Trafalgar International (GCAN) Share-based Compensation (2017 - 2025)
Trafalgar International (GCAN) posted Share-based Compensation of $1800.0 for Q1 2025, down 85.31% on a QoQ basis from $12250.0 in Q3 2019.
Powered by 
Analysis
Trafalgar International (GCAN) Share-based Compensation (2017 - 2025) Analysis & Trends
Trafalgar International has reported Share-based Compensation for 4 years, with the latest figure at $1800.0 in Q1 2025.
- On a quarterly basis, Share-based Compensation changed N/A year-over-year to $1800.0 in Q1 2025; TTM through Mar 2025 was $16550.0, a N/A change from a year earlier, with the FY2019 full-year figure at $88130.0, changed N/A from the prior year.
- Share-based Compensation was $1800.0 for Q1 2025 at Trafalgar International, down from $12250.0 in the prior quarter.
- The five-year high for Share-based Compensation was $1800.0 in Q1 2025, with the low at $1800.0 in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | -950.00 Mn |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | 166.00 Mn |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | 298.00 Mn |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | - |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 249.00 Mn |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | - |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | 277.20 Mn |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | 67.26 Mn |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | 19.00 Mn |
| 10 | Trafalgar International | 217,335.05 | 217,335.05 | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2025 | 1,800.00 |
| Sep 30, 2019 | 12,250.00 |
| Jun 30, 2018 | 2,500.00 |
| Mar 31, 2018 | 2,500.00 |
| Dec 31, 2017 | 2,500.00 |
| Sep 30, 2017 | 2,500.00 |
| Jun 30, 2017 | 500,000.00 |
| Mar 31, 2017 | 525,000.00 |